Search Result "CEBPA mutated AML."
The Evolving AML Genomic Landscape: Therapeutic Implications
Journal: Current Cancer Drug Targets
Volume: 20 Issue: 7 Year: 2020 Page: 532-544
Author(s): Sachi Horibata,George Alyateem,Christin B. DeStefano,Michael M. Gottesman
Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges
Journal: Current Pharmaceutical Design
Volume: 23 Issue: 29 Year: 2017 Page: 4303-4310
Author(s): Yuan Ling,Zikang Zhang,Hua Zhang,Zunnan Huang
Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach
Journal: Cardiovascular & Hematological Disorders-Drug Targets
Volume: 18 Issue: 3 Year: 2018 Page: 199-207
Author(s): Elumalai Suguna,Rahman Farhana,Elangovan Kanimozhi,Pindigiri Sai Kumar,Govindasamy Kumaramanickavel,Chitralekha Sai Kumar
Acute Myeloproliferative Disease
Ebook: Physiopathogenesis of Hematological Cancer
Volume: 1 Year: 2012
Author(s): Eduardo Magalhaes Rego,Mariana Tereza de Lira Benicio
Doi: 10.2174/978160805259211201010201
The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Journal: Current Pharmaceutical Biotechnology
Volume: 17 Issue: 1 Year: 2016 Page: 6-19
Author(s): Rakel B. Forthun,Carina Hinrichs,Tara H. Dowling,Ãystein Bruserud,Frode Selheim
Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Journal: Current Cancer Therapy Reviews
Volume: 9 Issue: 3 Year: 2013 Page: 181-219
Author(s): Ugo Testa
Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Journal: Current Cancer Therapy Reviews
Volume: 4 Issue: 1 Year: 2008 Page: 31-49
Author(s): Ugo Testa
Development of personalized molecular therapy for acute myeloid leukemia
Journal: Current Pharmaceutical Biotechnology
Volume: 17 Issue: 1 Year: 2016 Page: 20-29
Author(s): Caroline B.N. Engen,Ehsan Hajjar,Bjørn T. Gjertsen
Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Journal: Current Pharmaceutical Biotechnology
Volume: 17 Issue: 1 Year: 2016 Page: 52-70
Author(s): Elise Aasebø,Rakel B. Forthun,Frode Berven,Frode Selheim,Maria Hernandez-Valladares
Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 18 Issue: 14 Year: 2018 Page: 1936-1951
Author(s): Raghav Dogra,Rohit Bhatia,Ravi Shankar,Parveen Bansal,Ravindra K. Rawal